Mather Group, Llc. Veracyte, Inc. Transaction History

Mather Group, Llc.

$8.58 Billion
Q1 2025

A detailed history of Mather Group, Llc. transactions in Veracyte, Inc. stock. As of the latest transaction made, Mather Group, Llc. holds 130 shares of VCYT stock, worth $3,430. This represents 0.0% of its overall portfolio holdings.

Number of Shares

130

Holding current value

$3,430

% of portfolio

0.0%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2025 Apr 25, 2025	BUY	$29.65 - $46.14 $3,854 - $5,998	130 New	130 $3,000
Q1 2024 Apr 08, 2024	BUY	$21.0 - $29.1 $2,730 - $3,783	130 New	130 $2,000

Others Institutions Holding VCYT

# of Institutions

306

Shares Held

79.1M

Call Options Held

15.5K

Put Options Held

16.7K

Vanguard Group Inc Valley Forge, PA

8.26M
Shares

$218 Million
0.0% of portfolio
Black Rock Inc. New York, NY

7.79M
Shares

$206 Million
0.0% of portfolio
Artisan Partners Limited Partnership Milwaukee, WI

5.24M
Shares

$138 Million
0.27% of portfolio
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl

3.94M
Shares

$104 Million
1.26% of portfolio
Wellington Management Group LLP Boston, MA

3.85M
Shares

$102 Million
0.02% of portfolio

View Full List

About VERACYTE, INC.

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $1.89B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

More about VCYT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mather Group, Llc., based on Form 13F filings with the SEC.

News

Stay updated on Mather Group, Llc. with notifications on news.

Account